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Abstract
Purpose Hematology–oncology patients undergoing chemo-
therapy and hematopoietic stem cell transplantation (HSCT)
recipients are at risk for oral complications which may cause
significant morbidity and a potential risk of mortality. This
emphasizes the importance of basic oral care prior to, during
and following chemotherapy/HSCT. While scientific evi-
dence is available to support some of the clinical practices
used to manage the oral complications, expert opinion is
needed to shape the current optimal protocols.
Methods This position paper was developed by members of the
Oral Care Study Group,Multinational Association of Supportive
Care in Cancer/International Society of Oral Oncology
(MASCC/ISOO) and the European Society for Blood and Mar-
row Transplantation (EBMT) in attempt to provide guidance to
the health care providers managing these patient populations.
Results The protocol on basic oral care outlined in this posi-
tion paper is presented based on the following principles:
prevention of infections, pain control, maintaining oral func-
tion, the interplay with managing oral complications of cancer
treatment and improving quality of life.
Conclusion Using these fundamental elements, we developed
a protocol to assist the health care provider and present a
practical approach for basic oral care. Research is warranted
to provide robust scientific evidence and to enhance this
clinical protocol.
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Introduction
Hematology–oncology patients and patients undergoing
hematopoietic stem cell transplantation (HSCT) are a unique
cancer patient population. The main characteristic of this
patient population is that they experience myelosuppression
and immunosuppression due to their disease, the cancer ther-
apy or both and immune-mediated outcomes in survivorship.
Frequently, all blood lineages are affected resulting in neutro-
penia, thrombocytopenia and anemia.
This damage to the blood cells and immunosuppression
result in a common profile of oral complications that include
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infections, bleeding and anemia-related oral manifestations
(75). Furthermore, direct and indirect effects of cytotoxic
therapies to oral tissues lead to a series of additional compli-
cations. For example, mucositis, dry mouth and dysgeusia are
frequently observed in these patients (Table 1). Oral compli-
cations differ in their timing and duration with some referred
as early complications, while some develop later following
cancer treatment presenting survivorship issues.
Oral complications in these patient populations are com-
mon and estimated to affect 80 % of patients [1–4]. These oral
complications have a significant impact on the patient’s oral
function, including the basic need to eat, drink or speak. Pain
is also often associated with these oral complications and may
lead to increased need for systemic narcotics, increased length
of stay at hospital and an increased risk for life-threatening
systemic infections [5]. All these sequelae may lead to im-
paired health-related quality of life (QoL) adversely affecting
the patient and his or her family. Some patients have rated oral
mucositis as the most distressing aspect of anti-cancer treat-
ment [6]. Therefore, it is well-recognized that attempts should
be made to prevent oral complications, ease the patient’s pain
and minimize late consequences.
Several oral care guidelines have been published in an
attempt to assist the clinician [7–14]. However, the clinical
practice of oral care varies between and within centers and
may not always be optimal. There are various reasons for this,
including the availability of oral/dental care services in cancer
centers, difficulty with implementing guidelines into daily
practice, lack of consistency between various guidelines and
preference of traditional views over scientific evidence [15].
The aim of this position paper is to clearly state the recom-
mendation of the Multinational Association of Supportive
Care in Cancer/International Society of Oral Oncology
(MASCC/ISOO) and the European Society for Blood and
Marrow Transplantation (EBMT) for basic oral care in pa-
tients with hematologic cancer and those undergoing HSCT.
This position paper does not intend to detail the specific
management protocols of various oral complications related to
the underlying disease or related to the cancer treatment. An
overview of such oral complications is included in the
Table 1 Oral complications in hematology–oncology patients and HSCT recipients




Tissue-specific manifestations Mucosa Mucositis + +
Atrophy and burning, paleness (anemia) +
Neutropenic ulcer +
Lichenoid, erythema and ulcers (cGVHD) +
Pyogenic granuloma +
Salivary glands Salivary gland hypofunction + +
Sialadenitis + +
Mucocele (cGVHD) +
Musculo-skeletal Loss of elasticity, reduced range of motion and limited mouth
opening (i.e. scleroderma-like manifestations) (cGVHD)
+
Drug-induced osteonecrosis of the jaw +
Temporomandibular disorders +
Sensory disturbances Dysgeusia + +
Neuropathy +
Tooth hypersensitivity +
Teeth and gingivae Increased dental demineralization and caries +
Gingival enlargement +
Desquamative gingivitis (cGVHD) +
Acute periodontal infections (symptomatic) + +
Pre-existent chronic periodontal infections (asymptomatic) + +
Non-tissue-specific manifestations Bleeding + +
Infection—bacterial, viral, fungal + +
Squamous cell carcinoma +
Post-transplantation lymphoproliferative disorder +
Developmental disturbances of teeth and craniofacial growth
in pediatric patients
+
HSCT hematopoietic stem cell transplantation, cGVHD chronic graft versus host disease
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systematic reviews of the MASCC/ISOO and is of assistance
in addressing: bisphosphonate osteonecrosis [16], dysgeusia
[17], oral fungal infection [18], oral viral infection [19], dental
disease [20], osteoradionecrosis (ORN) [21], trismus [22],
oral pain [23], xerostomia and salivary gland hypofunction
[24, 25] and mucositis [26–34].
Basic oral care
Basic oral care (BOC) is defined as the activities that should
be part of the patient’s routine care during periods of cancer
treatment in order to maintain good oral health and reduce the
risk for local inflammation and infection, as well as systemic
infection originating from the oral cavity.
The objectives of BOC are the following: (1) prevention of
infection: to prevent infections of the oral mucosa and the
periodontium and to prevent regional spread and systemic
infection; (2) pain control: reduce discomfort and pain in the
mouth; (3) maintain oral functions: promoting oral nutritional
intake, oral fluid intake and capability to speak; (4) managing
the complications of the cancer treatment: reduce the adverse
effect of radiation therapy, chemotherapy and newer targeted
therapies (Table 1); and (5) improve QoL of the patient (Fig. 1).
The recommendations will be presented per objective. How-
ever, some practice recommendations address several objectives.
These objectives have relevance before, during and after
cancer therapy. Prevention and management of long-term com-
plications and maintenance of oral and dental health are relevant




A comprehensive dental and oral evaluation is the recom-
mended standard of care prior to high-dose chemotherapy/
HSCT in order to eliminate sources of infection, both
odontogenic and non-odontogenic. The dental treatment plan
should be definitive. It has been shown that dental treatment
prior to chemotherapy/HSCT may prevent the additional
death of 18 out of every 10,000 patients and may reduce
systemic infections by approximately one-third (250 versus
318 out of every 1,000 patients) [35]. Ideally, an initial ap-
pointment should be scheduled as early as possible in order to
allow sufficient time to deliver emergent and urgent dental
needs including dental extractions as well as professional
periodontal care (e.g. dental cleaning and oral hygiene instruc-
tion) and to allow time for tissues to heal post-operatively/
post-dental extractions, preferably with a healing period of
2 weeks. Principles of treatment planning in patients prior to
chemotherapy were suggested by an experts’ forum and can
be found online [1, 13]. Nevertheless, time constraints as well
as the medical condition itself may require modification of the
dental treatment plan [36, 37]. Dental treatment planning
requires that the dentist understands principles of oncology
care, the diagnosis and treatment plan for the patient. It also
requires close consultation with the medical team especially
regarding unresolved oral health issues that may interrupt or
complicate cancer treatment. Integrated health care teams
promote integrated health care planning. Patients need to be
informed about the dental treatment plan. There may be elec-
tive additional dental needs at the time of the examination that
can be addressed after the chemotherapy or HSCT, when the
patient’s overall health status allows, and it has been approved
by the medical management. Close coordination and commu-
nication between the different disciplines involved is therefore
necessary and is facilitated by integrated health care teams.
Pain control
Prior to chemotherapy or HSCT, the dental health care pro-
vider should take steps to ensure no traumatic and anatomic
factors may induce pain during and after cancer treatment.
Therefore, as part of the dental evaluation, the dentist should
eliminate potential sources of intra-oral trauma such as ill-
fitting dentures, orthodontic appliances, deficient/rough resto-
rations, traumatic dentition and dental calculus.
Furthermore, cancer therapy itself commonly results in
pain [38, 39, 23]. A consultation with an oral medicine spe-
cialist or a dentist experienced in managing oral complications
is recommended if atypical pain develops during the delivery
of oncology care.
Maintaining oral function
Based on the need to eliminate sources of infection prior to
chemotherapy, non-restorable teeth, including exposed root
tips, severely periodontally involved teeth, and impacted teeth
with signs of pericoronitis, should be extracted. Due to time
constraints, a determinative approach should be adopted for
restorable teeth (i.e. tooth extraction if there is insufficient time
to confirm that a focus of pulpal/periapical infection is resolved,
and sites of periodontal infection require definitive manage-
ment). Often, in neglected dentitions, this principle dictates
multiple extractions. The elimination of sharp or fractured teeth,
restorations and prostheses will prevent trauma to the oral
mucosa and thus will reduce risk for oral bleeding and infec-
tion. The dentist should consider a dental plan that will restore
the occlusal surface to the level that will allow the patient to eat
comfortably. The medical team should be aware of the patient’s
oral status and adjust foods to the chewing capabilities of the
patient. A nutritionist’s consultation may be needed.
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Managing oral complications of treatment
Considering that this section is aimed at patients pre-chemo-
therapy/HSCT, it is unlikely that they would have oral com-
plications related to their cancer treatment. The underlying
disease however may present with oral manifestations. The
medical and dental team should recognize the potential for
oral involvement of the underlying disorder and refer the
patient for a complete oral evaluation if an oral symptom is
reported or oral lesion is observed.
QoL
It is important to provide support and help the patient to
understand what is expected during chemotherapy or HSCT;
oral survivorship issues can be introduced, for example, the
expected and usually reversible mucositis and hyposalivation.
Possible long-term consequences and prevention strategies
should be communicated. Assistance of clinical coordinators




Maintenance of good and intensified oral hygiene is a funda-
mental component of BOC. Gingival and mucosal inflamma-
tion caused by oral bacteria and mucosal barrier injury in-
creases the risk of bacteremia. Intensive oral hygiene can
reduce the incidence and severity of mucositis [40, 41]. Ad-
ditionally, it has been reported that oral and periodontal as-
sessment and management reduce the risk of infection and
fever associated with oral conditions [42–45]. Lastly, mini-
mizing gingivitis and periodontitis will result in less gingival
bleeding. Therefore, patients benefit from maintaining good
oral hygiene thereby keeping the oral microbial load low.
Oral hygiene refers to the actions taken to remove dental
plaque from the teeth, to reduce the amount of oral bacteria in
the oral cavity and to wash away solid debris. Plaque left on
the gingival margin may cause gingivitis, which can lead to
bleeding of the gums and infection in immunocompromised
patients. Compliance may be compromised due to oral pain,
nausea and other complications during cancer treatment; how-
ever, it is important to encourage the patient to adhere to the
treatment protocol. The additional use of topical anesthetics/
analgesics can help make this task easier in times when oral
mucositis is present such as viscous xylocaine, dyclonine or
diphenhydramine for those with allergies to esters and amides;
topical analgesics such as doxepin and opioids may also
reduce pain thus facilitating oral care [23]. When oral hygiene
is compromised, the addition of chlorhexidine (CHX) as an
oral antiseptic could be considered due to its reducing impact
on the oral microflora. The MASCC/ISOO clinical practice
guidelines found no evidence to support CHX rinse in the
management of oral mucositis; however, this does not imply
that it should not be used for other purposes, such as preven-
tion of infection. Topical applications may cause local adverse
events (for example, CHX may induce reversible staining of
dental and oral tissues), and the patient should be so informed.
A combination of different oral hygiene products will
achieve best removal of plaque from all surfaces of the teeth.
Brushing should be continued two to three times a day. An
ultra-soft or a soft toothbrush with bristles softened in hot
water is preferred. Air-drying the toothbrush between uses is
recommended. The toothbrush should be replaced regularly;
in addition, some authors recommend the replacement of
toothbrush after each neutropenic cycle [46]. Toothpaste with
fluoride is recommended [47]. High concentration fluoride
toothpastes (e.g. 1.1 % sodium fluoride) are available by
prescription and should be provided if increased risk of dental
caries is anticipated. A non-mint-flavored toothpaste may be
suitable during days of mucosal injury. Likewise, toothpastes
containing sodium dodecyl sulfate (surfactant) should be
avoided if it irritates the mucosa. Brushing with sponge
brushes is optional but less effective to remove dental plaque
and preventing gingivitis [48], although with the addition of a
CHX solution, effectiveness increases [48]. Additional mea-
sures to remove dental plaque from between teeth, crowns/
bridges or dental implants and from the tongue should be
continued using devices that the patient is familiar with in
order to avoid self-injury due to lack of experience [49].
Frequent rinsing with bland solutions is recommended
although it should be emphasized that oral rinses are not a
substitute for mechanical cleaning. The neutral formulas are
basically salty water and/or baking soda rinse (0.9 % saline
and/or 0.5 % sodium bicarbonate solution, respectively) [7,
13]. Oral rinses with active agents can be combined as long as
there is no antagonism between the active agents (for example,
calcium phosphate rinse, CHX rinse) [7, 13]. The efficacy of
these agents for mucositis prevention is debated in the litera-
ture. However, the anti-microbial effect of CHX is not
questioned, and the washing effect of these liquids is valid.
Notwithstanding that, CHX use is limited to twice daily for the
duration of the neutropenia [50–52]. The non-alcoholic and
non-flavored CHX digluconate 0.12–0.2 % solution may be
easier to tolerate for patients with sensitive oral mucosa.
Scientific evidence about the effectiveness of CHX in various
concentrations, duration of rinse and cross-reaction is avail-
able in the literature [53, 54]. Oral adverse effects are usually
reversible (teeth and tongue discolouration and taste changes)
[55]. Possible substitute for topical disinfectants are
octenidine and polyhexanide.
Removable dental prosthesis should be cleaned in a similar
manner with mechanical aids and multiple washes, and when
not in use (during nights, or as often as the patient can
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accommodate), the dentures should be placed preferably in a
cleaning solution or in water. A range of cleaning solutions for
dentures is available (e.g. CHX, enzymes, sodium hypochlo-
rite, oral rinses or peroxide solutions). However, there is
limited evidence to suggest the use of a specific cleaning
solution or recommend that one solution should be preferred
over another in terms of health of the denture-bearing mucosa
[56]. Despite this, however, the use of a watery solution to
clean the dentures and in which to store the dentures when not
in use will assist in maintaining the integrity of the acrylic.
Other components of the BOC refer to prophylaxis against
oral candidiasis and viral reactivation [19, 18]. The protocols for
this can vary considerably between medical centers. This vari-
ability may reflect the doctrine of the medical team in a certain
location but also the geographical variability in the oral micro-
flora and resistant strains [57]. It is advised that the oral cavity be
examined on a daily basis for early changes including possible
signs of oral infection. An oral medicine specialist or experi-
enced dentist may assist whenever oral pathology is suspected.
Pain control
Pain control is an important element, particularly since during
this period, oral mucositis may develop [58–60]. This topic
has been extensively reviewed [23, 7, 61, 62, 13]. Generally, it
is important to conduct a pain score on a regular basis. There
are several pain ladders that can be used to score the pain level
[63, 10].
Treatment will be adjusted individually according to the
patient response to first lines of treatment. These include
topical analgesics/anesthetics and mucosal coating agents
(listed in Guide for Oral Care in Cancer Therapy [7]) and
non-opioids and opioids analgesics (pain management is
reviewed elsewhere) [62, 31]. The advantage of topical agents
is the paucity of adverse effects. However, most of the
evidence-based data refer to systemic medications, including
patient-controlled analgesia [12, 64]. The importance of neu-
ropathic pain in cancer patients due to chemotherapy and in
tissue damage due to mucositis has been of increasing interest
and is an important reason for pain continuing despite the use
of topical agents and nociceptive analgesics [23, 62]. Non-
pharmacologic modalities (such as low-level laser therapy,
relaxation/imaginary techniques, hypnosis) to relieve pain
are well reported in the literature and can be used as an
adjunctive modality [62].
Maintaining oral function
Pain control alone is insufficient to allow oral function during
the time period at risk for oral mucositis. Another early effect of
chemotherapy is dry mouth. Without the lubricating effect of
saliva, the oral mucosa is in continuous friction with other
mucosal surfaces, teeth and with oral intake. The ability to
eat, swallow and speak can be impaired when the mouth is
dry. Therefore, interventions to keep the mouth moist are im-
portant. This includes palliation by sipping or spraying water or
various saliva substitutes and mechanical-taste stimulants
(chewing gum, sweet–sour candies) and the use of frequent
bland rinses [7, 24, 13]. Some clinicians suggest using the spray
or mouth-rinse during daytime and gel during night since the
moisturizing effect of the more viscous consistency of the gel
tends to last longer. It is important that any saliva stimulants are
sugar-free and low in acid in order to avoid increased risk for
dental decay, tooth sensitivity and erosion. Likewise, keeping
the lips lubricated will prevent lips from getting dry and fis-
sured. Some clinicians prefer lanolin- or cocoa butter-based
lipsticks/creams over petroleum-based products.
The patient’s diet should be adjusted to the mucosal sensi-
tivity level. This may include avoiding crispy/rough foods and
acidic, spicy and hot foods in order to increase the likelihood
that the diet will be tolerable, particularly if oral mucositis is
evident. If topical anaesthetics are used to control mucosal
sensitivity, patients should be instructed to chew and swallow
carefully in order to avoid trauma or aspiration. A nutrition
specialist and the responsible physician should be consulted if
food intake is limited.
Managing oral complications of chemotherapy/HSCT
The list of acute oral complications (Table 1) is long and repre-
sents the complexity of these patients. This topic is beyond the
scope of this paper. Generally, each of these diagnoses should be
addressed separately according to the current best evidence.
QoL
QoL questionnaires, such as EORTC OH-17 and OHIP-14,
may facilitate the monitoring of the oral complications. The
combination of pain control, prevention of local infection and
maintaining saliva secretion contribute considerably to oral
health-related QoL. However, some of the oral complaints
may resolve with time in some patients such as taste change
or saliva dysfunction. For example, most patients will regain
taste function as early as a few weeks after the end of chemo-
therapy/HSCT, while in others, taste dysfunction may persist
for as long as 2 years post-HSCT [65]. Despite difficulties, it is
important to encourage the patient to maintain oral intake
while suffering from dysgeusia [66, 17].
Dry mouth also impacts QoL. As described above, com-
plaints can be relieved with systemic sialogogues and to some
extent by stimulation by topical means. Studies have shown
that patients consider the complications of oral mucositis and
dry mouth as very debilitating when asked for their perception
of the entire period of hospitalization following HSCT [67].
Therefore, the health care provider should address these com-
plaints seriously and support the patient.
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After chemotherapy/HSCT
Prevention of infections
Infections developing after chemotherapy/HSCTare common
in two instances. Firstly, when white cell counts are low, the
patient is at risk for infections; the most common are candidal
and herpetic infections [18, 19]. These immunosuppressed
patients are likely to be prescribed with antibiotics, which in
turn will change the oral microflora and will contribute to
emergence of oral candidiasis. Therefore, if the patient is
neutropenic or the dose of an immunosuppressive agent is
increased, a prophylactic dose of an anti-fungal and anti-viral
may be considered, if not already in place. Secondly, when a
dry mouth is long-standing, the patient is at risk of oral
candidiasis and dental damage. Therefore, if repeated candidal
infections occur, the clinician should consider instituting a
prophylactic anti-fungal treatment. In patients treated with
topical corticosteroids for oral chronic graft versus host dis-
ease (cGVHD) (see below), the risk for oral candidiasis further
increases. For effective prevention of oral candidiasis, in pa-
tients having dentures, the denture should be decontaminated
with the same anti-microbial agent to prevent recontamination
of the oral cavity by the denture’s microbial flora.
Dental disease should be considered as a source of infec-
tion and therefore should be managed routinely. Risk factors
for dental decay, such as hyposalivation, should be addressed.
Dental providers must be informed and may need to be
directed with respect to avoiding invasive treatment. Proce-
dures that generate aerosols (e.g. removal of dental plaque
deposits using an ultrasonic scaler), which may lead to aspi-
ration, should be minimized if the patient is immunosup-
pressed. It is critical that dental treatment be provided in the
context of the systemic status of the patient. Integrated med-
ical and dental teams function best in this regard. The nursing
team should encourage patients to visit an experienced dental
professional to address dental needs whenever blood counts
stabilize and to consult with the oncology team to assist in
dental care, specifically surgical intervention. Immune recon-
stitution may take months after the HSCT, even when hema-
tological status is apparently normal and any dental interven-
tion should be provided in the context of systemic health, and
again with experienced health care teams [68].
Pain control
Pain aetiology in the long-term post-transplant phase differs
from acute pain in the immediate time period post-chemother-
apy/HSCT. Chronic mucosal diseases such as GVHD become
the main reason for pain. Symptomatic gingival involvement
of cGVHD (desquamative gingivitis) may further limit the
patient’s ability to brush the teeth. In addition, local infection,
dental disease and neuropathic causes of oral pain are
common causes of oral pain in patients following chemother-
apy or in HSCTsurvivors. Topical palliative treatment for oral
cGVHDmay be helpful [8, 69]. In addition to therapy directed
to the pain, it is important to direct the therapy to the under-
lying disease, such as GVHD [8, 69]. Additional topical and
systemic and complementary pain management techniques are
available (reviewed in Epstein et al.) [62]. Expectations for full
control of pain are often limited by systemic adverse effects.
Maintaining oral function
Following the stabilization of blood counts and immune sta-
tus, patients should be advised to have dental needs addressed,
particularly the dental needs that were identified at the initial
appointment and were not considered a priority to complete
prior to the chemotherapy/HSCT. Treatment planning, partic-
ularly any potential surgical care, must be planned with the
medical team prior to intervention. Dental preventive strate-
gies can be reinforced. Dental rehabilitation (e.g. crowns,
bridges, dentures) will enable the patient to perform basic oral
functions. Medical centers may vary in the duration of the
time-window in which dental treatment is avoided.
The role of saliva in maintaining oral function is a constant
factor to consider. Methods to relieve salivary hypofunction
and/or xerostomia (the objective and subjective components
of dry mouth, respectively) may be best managed by use of
sialogogues when residual function is documented; palliation
is outlined above. Management modalities, such as acupunc-
ture and intra-oral electro-stimulator, may be considered
[24, 70].
Managing oral complications of chemotherapy/HSCT
In addition to chronic oral complications (i.e. cGVHD, dry
mouth), it is important to inform the patients with salivary
dysfunction that they are at increased risk for dental decay
[71]. Management of hyposalivation should be addressed. The
patient should be motivated to maintain oral hygiene, use fluo-
ride supplements (may be applied directly onto the dentition or
in individual trays, in-office as well as in-home methods), avoid
sweets and visit the dentist regularly. Artificial sweeteners can be
used as a substitute for sugar-based sweets. In this regard, xylitol
is preferred as it is not a digestible carbohydrate for Streptococ-
cus mutans, the main caries pathogen, and is a neurostimulant of
salivary secretion at higher doses (6–12 g day−1) [72]. In patients
with elevated risk to high plaque levels, the addition of CHX and
remineralizing agents such as calcium- and phosphate-based
products should be considered [73].
Chronic GVHD may manifest as scleroderma-like disease
with progressive damage decreasing the elasticity of oral
tissues. Limited mouth opening can disturb the patient’s basic
oral functions and may even put the patient at risk for aspira-
tion. The ease of performing and receiving dental care can be
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increasingly difficult because of this limited mouth opening;
unfortunately, little can be done to treat established scleroder-
ma [74, 75] although physiotherapy with an active exerciser
has been suggested to delay its progression. Additional phar-
macologic and surgical treatment modalities have been report-
ed [75].When scleroderma-type cGVHDhas developed, extra
care should be delivered to maintain oral hygiene and treat all
the dental needs beforemouth opening will limit the capability
to deliver dental treatment.
Patients with cGVHD are at a greater risk for oral squa-
mous cell carcinoma (SCC) [76]. Therefore, these patients
should be under routine surveillance by their oral health care
provider at least once a year or more frequently depending on
the level of oral cGVHD involvement.
Patients post-HSCT are often treated with high-dose ste-
roids, which in turn result in osteoporosis. The treatment for
osteoporosis is mostly with bisphosphonates, which are asso-
ciated with osteonecrosis of the jaws (ONJ). Additional anti-
resorptive and anti-angiogenesis drugs (denosumab,
bevacizumab and sunitinib) were reported to be associated with
ONJ [77]. The guidelines of the American Academy of Oral
and Maxillofacial Surgery address the prevention, treatment
and dental management of patients on these medications [78].
Children are also at risk of developing disturbances in
dental development and craniofacial growth (see ‘Pediatric
patient population’ section) particularly those subjected to
total body irradiation (TBI) at an early age. Eruption of teeth
should be monitored. Growth and development may also be
altered if puberty is affected by cancer therapy.
QoL
Dry mouth negatively impacts QoL [79]. It has been reported
that protocols including TBI have a greater tendency to cause
irreversible damage to the salivary glands [80]. However, less
toxic conditioning regimens may also have a long-term effect
on salivary function [81]. Following chemotherapy/HSCT,
dry mouth may be a result of the cytotoxic treatment itself
and also due to the use of multiple drugs that may affect
salivary secretion. Involvement of the salivary glands with
cGVHD can also reduce salivary secretion. Treatment trials
with systemic sialagogues may be offered to the patient [8].
Efficacy of sialagogues varies between patients, and adverse
effects and interaction with other medications have to be
considered. Persistent taste dysfunction is anticipated to affect
diet, oral intake and QOL, as well as impacting caloric and
nutrient intake with systemic implications [66].
Pediatric patient population
This has been covered in the guidelines on dental management
of pediatric patients receiving chemotherapy, HSCT and/or
radiation published by the American Academy of Pediatric
Dentistry. In this position paper, we would like to point to
several specific aspects [82, 9, 83].
Pain control
Children may have difficulty communicating and describing
their pain. Selection of a suitable pain scale depends on the
comprehension level of the patient. Topical oral administra-
tion of local anaesthetics such as lidocaine and benzocaine in
children should be avoided because of the risk for serious
adverse effects including deaths [84].
Prevention of infections
Ideally, children should be referred for an initial consult to a
pediatric dentist integrated with the cancer team [83].
Many children preparing for chemotherapy/HSCT have
pre-existing oral diseases, and those with high caries preva-
lence are at risk to develop new lesions. Advanced decay may
develop into a source of infection. Fluoride preparations in-
clude toothpastes, and fluoride supplements (gels, rinses or
varnishes) prevent dental caries. If a higher fluoride concen-
tration is required and the oral mucosa is sensitive, it is
recommended to use a neutral pH fluoride gel.
Maintaining oral function
Optimal oral care is needed in order to minimize oral problems
and discomfort before, during and after treatment as well as
the possible acute and long-term effects of therapy on the
developing craniofacial complex. Patient and parents’ educa-
tion plays a major role to achieve collaboration for long-term
surveillance. It is important to emphasize the need for regular
follow-up visits at a dental office and in complex cases with an
experienced oral medicine professional.
Managing oral complications of chemotherapy/HSCT
Generally, the same concepts of management used in adults are
applicable for children with the exception of drugs that are
registered specifically for use in adults. Additionally, it should
be noted that some of the clinical practice guidelines defined by
leading international organizations are generalizing adult and
pediatric patient population. Thus, effectiveness of a specific
intervention may not be guaranteed in pediatric patients.
One particular aspect of salivary dysfunction in children is
that they rarely complain about mouth dryness, even though
they objectively have a very low salivary output. An interview
that focuses on everyday situations may reveal signs and
symptoms of mouth dryness [85].
In respect to potential dental source for oral complication, it
was suggested that extraction of loose primary teeth will reduce
the risk for bleeding during periods of thrombocytopenia. This
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aspect should be discussed with the patient and the parents
during the dental clearance prior to the chemotherapy/HSCT.
Discussion
This position paper represents expert opinion of experienced
clinicians in the field of oral oncology, hematology and nurs-
ing. The systematic reviews about oral complications for can-
cer patients tend to state guidelines that are evidence-based
only. As a result, there are gray zones where practitioners are
left without guidelines and without consensus of how to care
for patients. This position paper provides a base for consensus
and provides recommendations with the goal of presenting
current best clinical practices.
An important aspect of promoting improved oral care of
patients undergoing chemotherapy/HSCT is by developing an
integrated treatment team including medical, dental, nursing,
nutrition, physical therapy and counseling providers. Training
and continuing education programs will ensure that the
knowledge will diffuse to an extensive community of health
care providers, which in turn could make a positive impact on
patients’ health care.
This position paper is directed at the entire multidisciplin-
ary health care team (Fig. 2). Terminology to describe the
Fig. 2 Suggested collaboration
of hematology/oncology and oral
medicine/dental teams as part of
basic oral care for oncologic
patients
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dental professional varies across the globe. A global term
(‘dentist’) was therefore used in this manuscript to refer to a
dental–oral care provider who is educated and experienced in
delivering oral health care for oncology patients. Such knowl-
edge should include understanding of the implications of the
medical background on the dental treatment plan and manag-
ing oral complications. The primary dentist in the community
may have an important role in the preparation of the patient
ahead of their chemotherapy/HSCT and in routine dental care
following the treatment but will need guidance of the oncol-
ogy team or the hospital dental team. The axis between the
primary dentist, the dentist/oral medicine specialist at the
cancer center and the medical team is essential for adequate
and timely clearance of dental and oral infections. To this end,
the dentist in the community should have continuing educa-
tion about the dental treatment planning in oncology in gen-
eral and for hematology-oncology patients and those follow-
ing HSCT. More information for dental practitioners about the
recommended treatment can be found in the literature [7, 20,
13, 83, 86].
As the profile of HSCT changes from myeloablative pro-
tocols to non-myeloablative protocols, the spectrum of oral
complications and management recommendations may also
change. Shorter nadir and lower incidence of severe oral
mucositis may lead to new insights with respect to the optimal
timing to resume routine dental treatment. On the other hand,
there may be more long-term cancer survivors, and patients
may be older and have more severe pre-existing dental pa-
thology and complications including an increase of the inci-
dence of GVHD.
In summary, oral and dental care must be recognized as a
critical component of care prior to and during chemotherapy/
HSCT and in survivorship. A multi-disciplinary team ap-
proach is the key for success in the management of oral
complications in hematology-oncology patients including
those undergoing HSCT.
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